QNTM — Quantum Biopharma Share News
0.000.00%
Last trade - 00:00NASDAQ RESUMED AT 07:10 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ RESUMED AT 07:50 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 PM
Brief: Quantum Biopharma Submits Investigational New Drug (Ind) Application To United States Food And Drug Administration (FDA)
NASDAQ RESUMED AT 01:12 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:50 AM
Brief: Quantum Biopharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
Brief: Quantum Biopharma Announces Appointment Of Principal Investigator For Planned Phase 2 Clinical Trial Of Lucid-21-302 (Lucid-MS) In Multiple Sclerosis
Brief: Quantum Biopharma Announces Peer-Reviewed Journal Publication Of Groundbreaking Clinical Trial With Unbuzzd
Brief: Quantum Biopharma Announces Positive Results Of The Clinical Study Report (CSR)
Brief: Quantum BioPharma Opposes CIBC & RBC’s Motion to Dismiss in Market Manipulation Case
Brief: Quantum Biopharma Purchases More Bitcoin Bringing Total Investment In Digital Assets To USD $5,000,000
Brief: Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP
Brief: Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202
Brief: Quantum Biopharma Announces Closing Of Final $2.42 Million Tranche Of $5 Million Total Financing On Improved Terms
FSD Pharma up on Canadian regulator's nod for human trials on MS drug
FSD Pharma rises on 1.9 mln share buyback plan